Temozolomide Prescribing Information Updated Under FDA’s Project Renewal Program
Temozolomide is the second drug to receive a labeling update under Project Renewal.
Temozolomide is the second drug to receive a labeling update under Project Renewal.
Adding ipilimumab to treatment with nivolumab does not provide a clinically meaningful benefit in patients with certain cancers, a meta-analysis suggests.
Image-guided dose escalation of radiotherapy does not improve outcomes in patients with glioblastoma receiving concomitant temozolomide, a phase 3 trial suggests.
This case study outlines the workup and treatment of glioblastoma multiforme.
UCPVax, an anti-telomerase vaccine, has demonstrated immunogenicity in a phase 2 trial of patients with MGMT unmethylated glioblastoma.
An ultrasound technique allows for delivery of albumin-bound paclitaxel across the blood-brain barrier in patients with recurrent glioblastoma, a study suggests.
Adagrasib produced responses in a phase 1/2 trial of patients with heavily pretreated, KRAS G12C-mutated solid tumors.
Artificial intelligence can predict survival in cancer patients using information from a patient’s initial consultation with an oncologist, a study suggests.
In mouse models, WP1122 outperformed temozolomide.
Chronic convection-enhanced delivery of topotecan was feasible and well tolerated in patients with recurrent glioblastoma.